CATX Stock Forecast & Price Target

Perspective Therapeutics is attractive fundamentally because its lead 212Pb platform combines targeted alpha radiation with a potentially differentiated safety profile, while its decentralized manufacturing model can improve supply reliability and reduce dependence on reactors or cyclotrons. The company’s pipeline offers multiple shots on goal, including VMT-α-NET in neuroendocrine tumors, VMT01 in advanced melanoma, and PSV359 with Keytruda in FAP-positive NSCLC and CRC, with early data showing encouraging activity and no DLTs at the 2.5 and 5 mCi dose levels. Despite development-stage risk, the stock appears undervalued relative to the underlying asset, supported by a >$1B peak U.S. sales opportunity for VMT and a construction of valuation cases that still implies meaningful upside as additional data emerge.

Perspective Therapeutics is viewed negatively because the updated VMT-α-NET data showed activity but not enough efficacy to clearly support the earlier blue-sky case, with ORR in cohort 2 slipping to 33% and cohort 3 only reaching 50% at a higher dose while DCR, though solid at 89% and 95%, is less compelling for investors. The outlook is further pressured by renal events that weakened the safety profile from “pristine” to “very clean,” plus execution risk tied to the planned phase III trial, manufacturing build-out, and a competitive landscape where rivals are further along. Although the company has roughly $200M of cash, the long development path, lack of marketed products, and reduced visibility for major catalysts raise financing and valuation risk.